Weng Y, Shen F, Li J, Shen Y, Zhang X
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Exp Clin Endocrinol Diabetes. 2007 Jul;115(7):455-60. doi: 10.1055/s-2007-973060.
MAP Kinase Phosphatase-1 (MKP-1) is a dual specific phosphatase selective for MAP kinases, and was believed to implicate in the development of cardiac hypertrophy. However, whether MKP-1 is involved in the pathogenesis of diabetic cardiomyopathy is still unknown. We employed streptozotocin (STZ)-induced diabetic Sprague-Dawley rats to study the alteration of the MKP-1 expressions in the left ventricular myocardium in diabetic and normal groups by immunohistochemistry and real-time quantitative reverse transcription-polymerase chain reaction. The weight, blood sugar and urine sugar were measured before and after model induction in both control and diabetic groups. Changes of heart ultrastructure were analyzed by using transmission electron microscopy. The data of weight, blood sugar and urine sugar indicated no significant difference between the two groups before animal model induction. Eight weeks after the induction of diabetes, the differences between the control and the diabetic groups in weight, blood sugar and urine sugar were significant ( P<0.01). When compared with control, diabetic myocardium ultrastructural changes included myofibrillar disarrangements, mitochondria disruption, and increase in nuclear membrane invaginations. A significant decrease of MKP-1 expression was observed in the diabetic rats' myocardium ( P<0.01). Our study provides experimental evidences that hyperglycemia could damage myocardial ultrastructure. Moreover, we provided first evidence that down-regulation of cardioprotective peptide MKP-1, the MAPK pathway negative regulator, in myocardium of streptozotocin-induced diabetic rats, which may contribute to the deterioration of cardiac function and lead to diabetic cardiomyopathy.
丝裂原活化蛋白激酶磷酸酶-1(MKP-1)是一种对丝裂原活化蛋白激酶具有选择性的双特异性磷酸酶,曾被认为与心肌肥大的发展有关。然而,MKP-1是否参与糖尿病性心肌病的发病机制仍不清楚。我们采用链脲佐菌素(STZ)诱导的糖尿病Sprague-Dawley大鼠,通过免疫组织化学和实时定量逆转录-聚合酶链反应研究糖尿病组和正常组左心室心肌中MKP-1表达的变化。在模型诱导前后测量对照组和糖尿病组的体重、血糖和尿糖。使用透射电子显微镜分析心脏超微结构的变化。体重、血糖和尿糖数据表明在动物模型诱导前两组之间无显著差异。糖尿病诱导8周后,对照组和糖尿病组在体重、血糖和尿糖方面的差异显著(P<0.01)。与对照组相比,糖尿病心肌的超微结构变化包括肌原纤维排列紊乱、线粒体破坏和核膜内陷增加。在糖尿病大鼠心肌中观察到MKP-1表达显著降低(P<0.01)。我们的研究提供了高血糖可损害心肌超微结构的实验证据。此外,我们首次提供证据表明,在链脲佐菌素诱导的糖尿病大鼠心肌中,心脏保护肽MKP-1(MAPK途径负调节因子)下调,这可能导致心脏功能恶化并引发糖尿病性心肌病。